SCHEMBL4858748

SCHEMBL4858748

CCc1ccc(Cc2c(OCc3ccccc3)nn(C(C)C)c2C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAPK1 P53355 1/20 0.40
SLC5A1 P13866 2/20 0.40
SLC5A2 P31639 2/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
SLC6A4 P31645 1/20 0.38
MPO P05164 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
BCHE P06276 3/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
CNR1 P21554 1/20 0.35
ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10064922 0.74 SLC5A1 (0.57) SLC5A1SLC5A2ALDH1A1LMNAHPGD
SCHEMBL4857102 0.73 SLC5A1 (0.38) SLC5A1SLC5A2ALDH1A1LMNAHPGD
SCHEMBL4860259 0.72 SLC5A1 (0.47) SLC5A1SLC5A2LMNAL3MBTL1HTR2C
SCHEMBL1268295 0.71 ALDH1A1 (0.45) DAPK1ALDH1A1LMNAHPGDTSHR
SCHEMBL17156356 0.71 NPC1 (0.47) SLC5A1SLC5A2ALDH1A1HPGDTSHR
SCHEMBL10064334 0.70 PDE1A (0.38) SLC5A1SLC5A2MPONPC1RAB9A
SCHEMBL4854533 0.68 TP53 (0.42) ALDH1A1LMNAHPGDTSHRMAPK1
SCHEMBL1268483 0.68 ALDH1A1 (0.41) DAPK1ALDH1A1LMNAHPGDTSHR
SCHEMBL1268365 0.68 ALDH1A1 (0.41) DAPK1ALDH1A1LMNAHPGDTSHR
SCHEMBL10064335 0.68 CHRM4 (0.38) SLC5A1SLC5A2ALDH1A1MAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439232-B2 Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 US disclosed
EP-1609799-A1 HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same SLC5A2, SLC5A1, UGGT1 DAPK1 2134/4885SLC5A1 2/4885SLC5A2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.